UniProtKB/Swiss-Prot P04798: Variant p.Thr461Asn

Cytochrome P450 1A1
Gene: CYP1A1
Feedback?

Variant information Variant position:

461 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Threonine (T) to Asparagine (N) at position 461 (T461N, p.Thr461Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In allele CYP1A1*4; displays similar catalytic efficiency toward estrogens when compared to the wild-type enzyme.. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs1799814 [ dbSNP | Ensembl ]

Sequence information Variant position:

461 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

512 The length of the canonical sequence.
Location on the sequence:

KVLSEKVIIFGMGKRKCIGE T IARWEVFLFLAILLQRVEFS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEFS

                              KALSEKVILFGLGKRKCIGETIARLEVFLFLAILLQQVEFS

Rhesus macaque                KVLSEKVILFGLGKRKCIGETIARWEVFLFLAILLQRVEFS

Mouse                         KRLSEKVTLFGLGKRKCIGETIGRSEVFLFLAILLQQIEFK

Rat                           KHLSEKVILFGLGKRKCIGETIGRLEVFLFLAILLQQMEFN

Rabbit                        KALTEKVLLFGLGKRKCIGETIGRLEVFLFLATLLQQVEFS

Sheep                         KVLSEKVIIFGLGKRQCIGEIIARLEVFLFLAILLHQVEFH

Cat                           KALSEKVILFGLGKRKCIGETIARLEVFLFLAILLQQVEFS

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 512	Cytochrome P450 1A1
Binding site	457 – 457	axial binding residue
Alternative sequence	190 – 512	Missing. In isoform 2.
Alternative sequence	419 – 512	Missing. In isoform 3.
Helix	460 – 477

Literature citations
Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone.
Kisselev P.; Schunck W.H.; Roots I.; Schwarz D.;
Cancer Res. 65:2972-2978(2005)
Cited for: FUNCTION; CATALYTIC ACTIVITY; CHARACTERIZATION OF VARIANT ASN-461 AND VARIANT VAL-462; BIOPHYSICOCHEMICAL PROPERTIES; PATHWAY; A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility.
Cascorbi I.; Brockmoller J.; Roots I.;
Cancer Res. 56:4965-4969(1996)
Cited for: VARIANT ASN-461; Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.
Solus J.F.; Arietta B.J.; Harris J.R.; Sexton D.P.; Steward J.Q.; McMunn C.; Ihrie P.; Mehall J.M.; Edwards T.L.; Dawson E.P.;
Pharmacogenomics 5:895-931(2004)
Cited for: VARIANTS ASP-45; THR-78; TRP-93; ARG-173; ASN-461; MET-482 AND ARG-492; Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus.
Jiang Z.; Dalton T.P.; Jin L.; Wang B.; Tsuneoka Y.; Shertzer H.G.; Deka R.; Nebert D.W.;
Hum. Mutat. 25:196-206(2005)
Cited for: VARIANTS ASP-45; THR-78; ASN-461 AND VAL-462;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.